Patents by Inventor Leung-Kei Siu

Leung-Kei Siu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibiotic testing and screening system
    Patent number: 10760110
    Abstract: The present invention provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from fully susceptible clinical isolates. This antibiotic testing and screening system of the present invention can efficiently and effectively evaluate antibiotics against specified resistance mechanisms in vitro and in vivo, and is suitable on the novel antibiotic development in against multidrug-resistant bacteria.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 1, 2020
    Assignee: KeMyth Biotech Co., Ltd.
    Inventors: Yu-Kuo Tsai, Leung-Kei Siu
  • TREATMENT OF DIABETES, TOLL-LIKE RECEPTOR 4 MODULATORS AND METHODS FOR USING THE SAME
    Publication number: 20190359658
    Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.
    Type: Application
    Filed: March 18, 2019
    Publication date: November 28, 2019
    Applicant: KeMyth Biotech Co., Ltd.
    Inventors: Leung-Kei Siu, Pele Choi-Sing Chong, Feng-Yee Chang, Chih-Hsiang Leng
  • Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same
    Patent number: 10287328
    Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 14, 2019
    Assignee: KeMyth Biotech Co., Ltd.
    Inventors: Leung-Kei Siu, Pele Choi-Sing Chong, Feng-Yee Chang, Chih-Hsiang Leng
  • ANTIBIOTIC TESTING AND SCREENING SYSTEM
    Publication number: 20180245125
    Abstract: The present invention provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from fully susceptible clinical isolates. This antibiotic testing and screening system of the present invention can efficiently and effectively evaluate antibiotics against specified resistance mechanisms in vitro and in vivo, and is suitable on the novel antibiotic development in against multidrug-resistant bacteria.
    Type: Application
    Filed: February 23, 2018
    Publication date: August 30, 2018
    Applicant: KeMyth Biotech Co., Ltd.
    Inventors: Yu-Kuo Tsai, Leung-Kei Siu
  • TREATMENT OF DIABETES, TOLL-LIKE RECEPTOR 4 MODULATORS AND METHODS FOR USING THE SAME
    Publication number: 20170260241
    Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 14, 2017
    Applicants: KeMyth Biotech Co., Ltd.
    Inventors: Leung-Kei Siu, Pele Choi-Sing Chong, Feng-Yee Chang, Chih-Hsiang Leng
  • USE OF OUTER MEMBRANE PORIN K36 PROTEIN (OMPK36) IN TREATMENT/PREVENTION/DIAGNOSIS OF ENTEROBACTERIACEAE INFECTION
    Publication number: 20130251748
    Abstract: The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or E. coli in central nervous system and/or peripheral blood circulation, which comprises administering an effective amount of an OmpK36/homologues or its derivatives to the mammal.
    Type: Application
    Filed: July 10, 2012
    Publication date: September 26, 2013
    Applicant: NATIONAL DEFENSE MEDICAL CENTER
    Inventors: Leung-Kei Siu, Feng-Yee Chang, Yung-Chung Lin, Chang-Phone Fung, Yip-Mei Liu, Jiun-Han Chen, Yu-Kuo Tsai, Pele Choi-Sing Chong, Chih-Hsiang Leng, Shih-Jen Liu, Hsin-Wei Chen
  • Test Kit for Detecting Klebsiella Pneumoniae Serotype K1 and Method Using Same
    Publication number: 20110287452
    Abstract: Disclosed are a test kit and method for sensitively and rapidly detecting Klebsiella pneumoniae serotype K1. By using immunochromatographic test, the test kit can sensitively, rapidly and specifically identify whether specimens contain Klebsiella pneumoniae serotype K1. The sensitivity of the test kit preferably attains 1.4×105 cfu/50?.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 24, 2011
    Applicant: NATIONAL DEFENSE MEDICAL CENTER
    Inventors: Feng-Yee Chang, Chang-Phone Fung, Leung-Kei Siu, Yung-Chung Lin, Kuo-Ming Yeh, Te-Li Chen